title: Strategies to target drugs to gliomas and CNS metastases of solid tumors.
abstract: The treatment for central nervous system metastases of solid tumors and gliomas is limited as the blood-brain barrier (BBB) is an obstacle to systemic therapy. Here, we review the physiochemical properties of the BBB and both current and new drug strategies to penetrate brain tumors. We focus on targeting receptor- or carrier-mediated transport mechanisms over the BBB used by drug conjugates, nanoparticles, polymer-based nanocarriers, siRNA, and antibodies.
authors.affiliation: Department of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands. milojkovickerklaan@gmail.com.|Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands. milojkovickerklaan@gmail.com.
authors.forename: B
authors.initials: B
authors.lastname: Milojkovic Kerklaan
authors.affiliation: Department of Preclinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
authors.forename: O
authors.initials: O
authors.lastname: van Tellingen
authors.affiliation: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
authors.forename: A D R
authors.initials: AD
authors.lastname: Huitema
authors.affiliation: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.|Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
authors.forename: J H
authors.initials: JH
authors.lastname: Beijnen
authors.affiliation: Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
authors.forename: W
authors.initials: W
authors.lastname: Boogerd
authors.affiliation: Department of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.|Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.|Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
authors.forename: J H M
authors.initials: JH
authors.lastname: Schellens
authors.affiliation: Department of Neuro-oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. d.brandsma@nki.nl.
authors.forename: D
authors.initials: D
authors.lastname: Brandsma
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000503:physiopathology; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents
keywords: Antibodies; Brain metastases; Glioma; Nanoparticles; Polymer-based nanocarriers; siRNA